Blinatumomab as a bridge to trasplantation in refractory Philadelphia chromosome negative b-cell acute lymphoblastic leukemia: a case report

被引：0
|
作者：
Rodriguez-Ferreras, A. [1 ]
Zapico-Garcia, I [1 ]
机构：
[1] Hosp Univ Cent Asturias, Unidad Gest Clin Farm, Avda Roma S-N, Oviedo 33011, Spain
来源：
ANALES DEL SISTEMA SANITARIO DE NAVARRA | 2019年 / 42卷 / 01期
关键词：
Blinatumomab; Philadelphia chromosome negative; Stem cell transplantation; Minimal residual disease; Refractory acute lymphoblastic leukemia; PHASE-II;
D O I：
10.23938/ASSN.0392
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Blinatumomab is a first class bispecific T-cell engager that has been shown to achieve negative minimal residual disease in patients with relapsed or refractory pre-B acute lymphoblastic leukemia after conventional chemotherapy. Nevertheless, there is little evidence about its role as an off label enhancer of cytological remission prior to stem cell transplantation (SCT). We describe the case of a patient with an excellent performance status who was allowed to undergo alogenic SCT after a single blinatumomab cycle, as well as the management of adverse events and the observed results.
引用
收藏
页码：75 / 78
页数：4
相关论文
共 50 条
  • [41] The combination of a tyrosine kinase inhibitor and blinatumomab in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia or Philadelphia chromosome-like acute lymphoblastic leukemia
    Wu, Xiaoxia
    Lu, Shenqi
    Zhang, Xinhui
    Yang, Zhen
    Sun, Aining
    Wu, Depei
    Zhou, Huifen
    Miao, Miao
    CANCER MEDICINE, 2024, 13 (17):
  • [42] Case Report: Blinatumomab therapy for the treatment of B-cell acute lymphoblastic leukemia patients with central nervous system infiltration
    Cao, Han-Yu
    Chen, Hui
    Liu, Song-Bai
    Gong, Wen-Jie
    Qian, Chong-Sheng
    Zhang, Tong-Tong
    Wan, Chao-Ling
    Huang, Si-Man
    Xu, Nan
    Dai, Hai-Ping
    Xue, Sheng-Li
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [43] B-Cell Acute Lymphoblastic Leukemia Presenting as Leukemia Cutis: A Case Report
    Afzal, Anoshia
    Mingola, Phillip
    Farooque, Umar
    Shabih, Sohaib
    Thomas, Cody A.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2020, 12 (10)
  • [44] Blinatumomab as frontline therapy for B-cell precursor acute lymphoblastic leukemia in a critically ill young adult: a case report
    Mendez-Guerra, Carolina
    Reyes-Farias, Carlos Ignacio
    Uribe-Ramirez, Luis
    Carrasco-Yalan, Antonio
    ANNALS OF BLOOD, 2024, 9
  • [45] PROGNOSTIC IMPACT OF CD20 EXPRESSION IN ADULTS WITH PHILADELPHIA CHROMOSOME NEGATIVE PRECURSOR B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA
    Djunic, I.
    Virijevic, M.
    Kraguljac-Kurtovic, N.
    Knezevic, V.
    Dragovic-Ivancevic, T.
    Novkovic, A.
    Mitrovic, M.
    Colovic, N.
    Vidovic, A.
    Suvajdzic-Vukovic, N.
    Tomin, D.
    HAEMATOLOGICA, 2016, 101 : 660 - 661
  • [46] Blinatumomab to improve the outcome of children with relapsed B-cell acute lymphoblastic leukemia
    J. L. Fuster
    F. Bautista
    B. González
    J. M. Fernández
    S. Rives
    J. L. Dapena
    Clinical and Translational Oncology, 2021, 23 : 1963 - 1966
  • [47] A balancing act: Blinatumomab use in a rare occurrence of Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia in an adolescent patient with Down syndrome
    Rav, Emily Simon
    Wahba, Andrew
    Patnaik, Anish
    Toruner, Gokce
    Hittle, Aline
    Toepfer, Laurie
    Roth, Michael
    Cuglievan, Branko
    Nunez, Cesar
    McCall, David
    PEDIATRIC BLOOD & CANCER, 2023, 70 (05)
  • [48] Use of Blinatumomab for Relapse Therapy of B-Cell Precursor Acute Lymphoblastic Leukemia
    Pawinska-Wasikowska, K.
    Wyrobek, E.
    Klekawka, T.
    Luszawska-Kutrzeba, T.
    Garus, K.
    Pietrys, D.
    Zaniewska-Tekieli, A.
    Wieczorek, A.
    Balwierz, W.
    PEDIATRIC BLOOD & CANCER, 2019, 66 : S251 - S251
  • [49] Clinical and pharmacologic aspects of blinatumomab in the treatment of B-cell acute lymphoblastic leukemia
    Portell, Craig A.
    Wenzell, Candice M.
    Advani, Anjali S.
    CLINICAL PHARMACOLOGY-ADVANCES AND APPLICATIONS, 2013, 5 : 5 - 11
  • [50] Benefit-Risk Assessment of Blinatumomab in the Treatment of Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    Stein, Anthony
    Franklin, Janet L.
    Chia, Victoria M.
    Arrindell, Deborah
    Kormany, William
    Wright, Jacqueline
    Parson, Mandy
    Amouzadeh, Hamid R.
    Choudhry, Jessica
    Joseph, Guiandre
    DRUG SAFETY, 2019, 42 (05) : 587 - 601
12345